Cisatracurium Fresenius Kabi
Cisatracurium Fresenius Kabi Uses, Dosage, Side Effects, Food Interaction and all others data.
Cisatracurium Fresenius Kabi is a nondepolarizing skeletal muscle relaxant for intravenous administration. Cisatracurium Fresenius Kabi acts on cholinergic receptors, blocking neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine. The neuromuscular block produced by cisatracurium besylate is readily antagonized by anticholinesterase agents once recovery has started. As with other nondepolarizing neuromuscular blocking agents, the more profound the neuromuscular block at the time of reversal, the longer the time required for recovery of neuromuscular function. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action.
Cisatracurium Fresenius Kabi Besylate is a nondepolarizing skeletal muscle relaxant for intravenous administration. Cisatracurium Fresenius Kabi Besylate acts on cholinergic receptors, blocking neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine. The neuromuscular block produced by cisatracurium besylate is readily antagonized by anticholinesterase agents once recovery has started. As with other nondepolarizing neuromuscular blocking agents, the more profound the neuromuscular block at the time of reversal, the longer the time required for recovery of neuromuscular function. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action.
| Trade Name | Cisatracurium Fresenius Kabi |
| Availability | Prescription only |
| Generic | Cisatracurium |
| Related Drugs | lorazepam, diazepam, fentanyl, Ativan, lidocaine, Valium, ketamine, midazolam, hyoscyamine, propofol |
| Type | |
| Formula | C53H72N2O12 |
| Weight | Average: 929.16 Monoisotopic: 928.507428607 |
| Protein binding | The binding of cisatracurium to plasma proteins has not been successfully studied due to its rapid degradation at physiologic pH. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | Netherlands |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Cisatracurium Fresenius Kabi is a skeletal muscle relaxant used to facilitate tracheal intubation, muscle relaxation in surgery, or mechanical ventilation.
For inpatients and outpatients as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation in the ICU.
Cisatracurium Fresenius Kabi is also used to associated treatment for these conditions: General Anesthesia, Skeletal muscle relaxation for mechanical ventilation, Smooth muscle relaxation prior to radiological procedures
How Cisatracurium Fresenius Kabi works
Cisatracurium Fresenius Kabi Besylate binds to the nicotinic acetycholine (cholinergic) receptors in the motor endplate and blocks access to the receptors. In the process of binding, the receptor is actually activated - causing a process known as depolarization. Since it is not degraded in the neuromuscular junction, the depolarized membrane remains depolarized and unresponsive to any other impulse, causing muscle paralysis.
Toxicity
Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.
Food Interaction
No interactions found.Cisatracurium Fresenius Kabi Drug Interaction
Moderate: digoxin, digoxinUnknown: aspirin, aspirin, charcoal, charcoal, epinephrine, epinephrine, sulfamethoxazole / trimethoprim, sulfamethoxazole / trimethoprim, ubiquinone, ubiquinone, copper gluconate, copper gluconate, glycerin, glycerin, acetaminophen, acetaminophen, bioflavonoids, bioflavonoids
Cisatracurium Fresenius Kabi Disease Interaction
Major: prematurity, burns, myasthenia gravis, paresis, pulmonary impair
Half Life
Elimination half-life of 22 minutes.
Elimination Route
Biliary and urinary excretion were the major routes of excretion of radioactivity (totaling >90% of the labeled dose within 7 hours of dosing), of which atracurium represented only a minor fraction.
Innovators Monograph
You find simplified version here Cisatracurium Fresenius Kabi
